Rapamycin and inulin for booster vaccine response stimulation (RIVASTIM)-rapamycin: study protocol for a randomised, controlled trial of immunosuppression modification with rapamycin to improve SARS-CoV-2 vaccine response in kidney transplant recipientsArticle Published on 2022-09-152022-11-15 Journal: Trials [Category] [DOI] 10.1186/s13063-022-06634-w PMC 바로가기
Anti-C5a antibody (vilobelimab) therapy for critically ill, invasively mechanically ventilated patients with COVID-19 (PANAMO): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trialArticle Published on 2022-09-072022-10-06 Journal: The Lancet. Respiratory Medicine [Category] [DOI] 10.1016/S2213-2600(22)00297-1 PMC 바로가기 [Article Type] Article
Dipeptidyl peptidase-1 inhibition in patients hospitalised with COVID-19: a multicentre, double-blind, randomised, parallel-group, placebo-controlled trialArticle Published on 2022-09-022022-10-06 Journal: The Lancet. Respiratory Medicine [Category] [DOI] 10.1016/S2213-2600(22)00261-2 PMC 바로가기 [Article Type] Article
Infliximab in the treatment of patients with severe COVID-19 (INFLIXCOVID): protocol for a randomised, controlled, multicentre, open-label phase II clinical studyArticle Published on 2022-09-022022-10-04 Journal: Trials [Category] [DOI] 10.1186/s13063-022-06566-5 PMC 바로가기 [Article Type] Article
Can a new formulation of opiate agonist treatment alter stigma?: Place, time and things in the experience of extended-release buprenorphine depotResearch article Published on 2022-09-012022-10-05 Journal: The International Journal on Drug Policy [Category] [DOI] 10.1016/j.drugpo.2022.103788 [Article Type] Research article
Influence of the SARS-CoV-2 outbreak on management and prognosis of new lung cancer cases, a retrospective multicentre real-life cohort studyArticle Published on 2022-09-012022-11-16 Journal: European journal of cancer (Oxford, England : 1990 [Category] [DOI] 10.1016/j.ejca.2022.06.018 PMC 바로가기
Immunogenicity and reactogenicity of an inactivated SARS-CoV-2 vaccine (BBV152) in children aged 2-18 years: interim data from an open-label, non-randomised, age de-escalation phase 2/3 studyClinical Trial Published on 2022-09-012022-10-05 Journal: The Lancet. Infectious Diseases [Category] [DOI] 10.1016/S1473-3099(22)00307-3 PMC 바로가기 [Article Type] Clinical Trial
Identification of COVID-19 patients at risk of hospital admission and mortality: a European multicentre retrospective analysis of mid-regional pro-adrenomedullinObservational Study Published on 2022-08-282022-10-05 Journal: Respiratory Research [Category] [DOI] 10.1186/s12931-022-02151-1 PMC 바로가기 [Article Type] Observational Study
Immunogenicity and safety of an inactivated SARS-CoV-2 vaccine (Sinopharm BBIBP-CorV) coadministered with quadrivalent split-virion inactivated influenza vaccine and 23-valent pneumococcal polysaccharide vaccine in China: A multicentre, non-inferiority, open-label, randomised, controlled, phase 4 trial중국에서 4가 스플릿-비리온 비활성화 인플루엔자 백신 및 23가 폐렴구균 다당류 백신과 함께 투여된 비활성화 SARS-CoV-2 백신(Sinopharm BBIBP-CorV)의 면역원성 및 안전성: 다기관, 비열등성, 공개 라벨, 무작위, 통제, 4상 시험Clinical Trial Published on 2022-08-262022-09-12 Journal: Vaccine [Category] [DOI] 10.1016/j.vaccine.2022.07.033 PMC 바로가기 [Article Type] Clinical Trial
Potential of FX06 to prevent disease progression in hospitalized non-intubated COVID-19 patients – the randomized, EU-wide, placebo-controlled, phase II study design of IXIONClinical Trial Published on 2022-08-192022-10-05 Journal: Trials [Category] [DOI] 10.1186/s13063-022-06609-x PMC 바로가기 [Article Type] Clinical Trial